Jonathon B. Cohen

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

Anas Younes, Armando Santoro, Margaret A. Shipp et al. · The Lancet Oncology · 2016 · 924 citations · Full text

Medicine, Hematology, Oncology +16

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

Philippe Armand, Andreas Engert, Anas Younes et al. · Journal of Clinical Oncology · 2018 · 754 citations · Full text

Medicine, Hematology, Oncology +17

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

Adam M. Petrich, Mitul Gandhi, Borko Jovanovic et al. · Blood · 2014 · 466 citations

Medicine, Oncology, Hematologic Oncology +9

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak et al. · The Lancet · 2021 · 454 citations · Full text

Medicine, Oncology, Pharmacology +12

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma

Margaretha G.M. Roemer, Robert Redd, Fathima Zumla Cader et al. · Journal of Clinical Oncology · 2018 · 367 citations · Full text

Life Sciences, Immunology, Oncology +17